Gary John Schiller MD

Oncology•Los Angeles, CA

Hematologic Oncology

Professor of Medicine, UCLA

Join to View Full Profile

10833 LeConte Ave, 42-121 CHSLos Angeles, CA 90095
Phone+1 310-825-5513
Fax+1 310-825-5513

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1984 - 1987
Keck School of Medicine of the University of Southern CaliforniaClass of 1984

Certifications & Licensure

CA State Medical License 1985 - 2027
FL State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2000 Sep 01
Completed
Phase 1, Phase 2
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2001 Sep 01
Unknown status
Phase 2
An Open-Label, Phase II (Proof Of Concept) Trial Of PKC412 Monotherapy In Patients With Acute Myeloid Leukemia (AML) And Patients With High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2002 Mar 01
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma Start of enrollment: 2004 Jun 01
Completed
Phase 1, Phase 2
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Start of enrollment: 2004 Aug 01
Unknown status
Not Applicable
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2007 Feb 01
Terminated
Phase 1
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
Completed
Phase 2
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia Start of enrollment: 2011 Mar 01
Completed
Phase 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
Roles: Contact, Principal Investigator
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Start of enrollment: 2014 Jan 01
Terminated
Phase 2
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Start of enrollment: 2014 Jul 01
Terminated
Phase 2
Stem Cell Gene Therapy for Sickle Cell Disease Start of enrollment: 2014 Dec 01
Active, not recruiting
Phase 1, Phase 2
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Start of enrollment: 2016 May 17
Completed
Phase 1
CPX-351 Plus Enasidenib for Relapsed AML Start of enrollment: 2019 Apr 12
Active, not recruiting
Phase 2
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
ACTIVE_NOT_RECRUITING
PHASE2
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2019 Jul 18
Terminated
Phase 1
Actuate 1901: 9-ING-41 in Myelofibrosis Start of enrollment: 2020 Aug 20
Completed
Phase 2
Roles: Contact
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Start of enrollment: 2021 Mar 17
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib Start of enrollment: 2019 Aug 12
Terminated
Phase 1
Roles: Contact
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications
COMPLETED
PHASE1, PHASE2
Roles: Principal Investigator, Contact
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Start of enrollment: 2016 Feb 10
COMPLETED
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies Start of enrollment: 2020 Jul 08
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Contact, Principal Investigator
Selinexor and Backbone Treatments of Multiple Myeloma Patients
RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator, Contact
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies Start of enrollment: 2020 Nov 06
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001) Start of enrollment: 2022 Jul 12
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Start of enrollment: 2018 Jan 02
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.
Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer
Blood Cancer Journal. 2025-04-03
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
Caspian Oliai, Sunmin Park, Lloyd E Damon, Brian A Jonas, Deepa Jeyakumar
Leukemia & Lymphoma. 2025-04-01
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Aaron C Logan
Leukemia. 2025-03-19

Journal Articles

Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AML
Alexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood

Abstracts/Posters

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent _-Thalassemia in the Northstar (HGB-204) Study
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent B...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Moving Toward Precision Therapy for Patients with AML: Clinical Challenges and Future Directions
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Authored Content

The Scientific Sessions from ASH 2021December 2021

Press Mentions

CIRM Grant Will Help Expand Patients’ Access to UCLA Clinical Trials for Stem Cell, Gene TherapiesOctober 27th, 2022
African-American Blood Donors Needed to Help People with Sickle Cell DiseaseOctober 4th, 2022
UCLA Jonsson Comprehensive Cancer Center Researchers at ASH 2021 Annual Meeting and ExpositionDecember 14th, 2021
Join now to see all